-
Clinical Ophthalmology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Optic nerve sheath fenestration in cryptococcal meningitis
Case report
(2118) Views (688) Full article downloads
Authors: Tatyana Milman, Neena Mirani, Roger E Turbin
Published Date October 2008
Volume 2008:2(3) Pages 637 - 639
DOI: http://dx.doi.org/10.2147/OPTH.S2096
Tatyana Milman1, Neena Mirani1,2, Roger E Turbin1
1Ophthalmology Department, Institute of Ophthalmology and Visual Science, 2Pathology Department, University Hospital, New Jersey Medical School, Newark, NJ, USA
Abstract: A patient with acquired immunodeficiency syndrome (AIDS) developed crytpococcal meningitis, complicated by papilledema and severe progressive visual loss despite medical therapy. Bilateral optic sheath fenestration resulted in significant improvement in vision and resolution of papilledema. Histopathologic evaluation of the optic nerve sheath demonstrated numerous cryptococci. Optic nerve sheath fenestration may be an effective treatment method when high intracranial pressure is contributing to visual loss, even in the presence of involvement of the optic nerve sheath by the fungus.
Keywords: optic nerve sheath, cryptococcal, meningitis, fenestration
- Journal Indexing
See where all the Dove Press journals are indexed
- Interested in being a peer-reviewer?
Click here to register.
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia
- Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%




